We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company's experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients who ...

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report), with a price target of $105.00. The company’s shares opened today ...

Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.

As I'm writing these lines, Novo Nordisk A/S (NVO) is down about 16% on the pre-market session after the news came out that its obesity drug — CagriSema — delivered disappointing trial results ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other weight loss stocks. Most people have at some point sought to include weight loss and ...

Novo Nordisk NVO announced that it plans to invest DKK 8.5 billion, translating to approximately $1.2 billion, to set up a new production facility in Odense, Denmark. Per NVO, the new site will ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production facility in Odense, Denmark. The scheme will be the first plant built in its ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $106.95, reflecting a -1.53% shift from the previouse trading day's closing. On the other hand, the Dow registered a loss of 0 ...